/
IMA
$5.87-$0.12 (-2.00%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$68.0M
11M shares
52-week range
$3.94 – $15.27
17% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-10.50
ImageneBio, Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
www.imagenebio.com- Employees
- 18
- IPO / List date
- Jul 28, 2025
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds IMA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 81,696 | $408.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMA yet.
